Summary
Biogen Inc. filed an 8-K report on September 14, 2015, detailing a significant debt financing event. On September 10, 2015, the company entered into an Underwriting Agreement to issue and sell $6.0 billion in aggregate principal amount of senior notes. This offering comprises four tranches with varying maturities and coupon rates, including notes due in 2020, 2022, 2025, and 2045. The proceeds from this offering, facilitated by Goldman, Sachs & Co. and Merrill Lynch, Pierce, Fenner & Smith Incorporated as underwriters, are expected to bolster Biogen's financial flexibility. The notes were registered under an automatic shelf registration statement filed on September 8, 2015, indicating a well-prepared and executed capital raise. Investors should note the fixed interest rates and maturity dates associated with each note series, which provide a clear picture of the company's debt obligations and cost of capital.
Key Highlights
- 1Biogen raised $6.0 billion through the issuance of senior notes.
- 2The offering consists of four tranches with maturities in 2020, 2022, 2025, and 2045.
- 3Interest rates for the notes range from 2.900% to 5.200%.
- 4The offering was conducted under an automatic shelf registration statement filed on September 8, 2015.
- 5Goldman, Sachs & Co. and Merrill Lynch acted as the representatives for the underwriters.
- 6The closing of the offering was expected around September 15, 2015.
- 7This move strengthens Biogen's liquidity and financial resources.